ASX:IPD
About ImpediMed
Founded and headquartered in Brisbane, Australia, ImpediMed is a global company with operations in the United States and Europe. We are the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition.
Leaders in BIS technology
ImpediMed and our subsidiaries pioneered the use of BIS technology, producing the first commercially available BIS devices in 1990. Our L-Dex® device was the first FDA-cleared medical technology to use BIS for the assessment of lymphedema. Use of L-Dex is now recommended in clinical practice guidelines of research centers and professional organizations across the country.
Expanding applications
In 2017, we launched SOZO®, the world’s most advanced BIS device. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure and allows measurement and tracking of various body composition parameters.
We are currently exploring the use of our advanced bioimpedance technology for a wide range of commercial applications, including:
- General health and weight management
- Bone content
- Protein-calorie malnutrition
Latest Media Releases
09/11/2022 11:04:00
Key Highlights
AstraZeneca extends its contract for a Phase IIb trial, which utilises 210 SOZO® devices to measure fluid volume in patients with chronic kidney disease, for an add…
Latest News
Stock Watch /
by -
5 years ago
04 Jun 2018 - Fairmont Equities managing director Michael Gable takes a technical look at AMP, Perpetual, Mayne Pharma Group, Impedimed, Vocus Group and Altium.
Market Reports /
by Rachael Jones -
6 years ago
17 Apr 2018 - The Australian share market closed flat today. At the closing bell the S&P/ASX 200 index closed 0.2 points higher to finish at 5,842. For the sectors Telcos were the …
Market Reports /
by Rachael Jones -
6 years ago
17 Apr 2018 - The Australian Share Market opened in positive territory, with the ASX 200 rising for the third day straight thanks to political tensions simmering. Stocks rallied on…
Company News /
by Kathy Skantzos -
6 years ago
23 Oct 2017 - ImpediMed (ASX:IPD), a global provider of medical technology, announces its study has been published in a peer-reviewed medical journal.
Company News /
by Jessica Amir -
6 years ago
29 Jun 2017 - ImpediMed Limited (ASX:IPD) has commenced its first commence sales for its SOZO platform in Europe and Australia, with shipments now underway.
Company News /
by Jessica Ellerm -
7 years ago
24 Apr 2017 - ImpediMed Limited (ASX:IPD) announces an at-home study in lymphoedema with its next generation device will soon commence in the US.
Market Reports /
by Carolyn Herbert -
7 years ago
20 Jul 2016 - Aus shares close 0.69% higher. IOT Group Limited (ASX:IOT) says its recent sales meetings regarding its Roam-e flying selfie drone product in New York exceeded expec…
Company News /
by David Chau -
7 years ago
20 Jul 2016 - Medical device company, ImpediMed Limited (ASX:IPD), enters strategic partnership with med-tech company, Redox.
Market Reports /
by Carolyn Herbert -
7 years ago
18 Jul 2016 - Aus shares close 0.53% higher. St Barbara Limited (ASX:SBM) has repurchased an additional US$40 million in aggregate principal of its US144A senior secure notes.
Company News /
by Jessica Ellerm -
7 years ago
18 Jul 2016 - ImpediMed Limited (ASX:IPD) announces it will partner with Vanderbilt University for a series of clinical trials involving patients and clinicians.
Market Reports /
by Carolyn Herbert -
7 years ago
30 May 2016 - Aus shares close flat. Galaxy Resources Limited (ASX:GXY) and General Mining Corporation have entered into a definitive takeover bid implementation agreement to merge…
Company News /
by -
8 years ago
03 Nov 2015 - ImpediMed Limited (ASX:IPD) has entered into an agreement with the Harvard Clinical Research Institute located in Boston, Massachusetts to advance research around BIS…
Company News /
by -
9 years ago
28 Apr 2015 - Impedimed Limited (ASX:IPD) secures another NCI designated cancer centre for the trial of its L-Dex technology.
Company News /
by -
9 years ago
09 Mar 2015 - Impedimed Limited (ASX:IPD) says another world-leading hospital has joined its L-Dex post approval trial.
Market Reports /
by -
9 years ago
05 Mar 2015 - Aus shares follow US lower. Impedimed Limited (ASX:IPD) says the MD Anderson Cancer Center has joined the L-Dex clinical trial.